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INTRODUCTION
ancer is often associated with abnormal activation of coag-
ulation leading to a prothrombotic state (1-6).
Thromboembolic disease has long been recognized as a compli-
cation of cancer. An increased incidence of thromboembolic
events has been noted in women receiving chemotherapy for
breast cancer (7-10). Weiss et al. noted a 5% incidence of throm-
boembolic disease in a cooperative group study of 433 breast
cancer patients treated with adjuvant chemotherapy (11).
Goodnough et al. reported a 17.6% incidence of thrombosis in
159 patients receiving a five-drug chemotherapy regimen for
stage IV (metastatic) breast cancer (12). 
Some chemotherapeutic agents used for cancer may induce
thrombosis but their biological alterations in the hemostatic sys-
tem are not  well understood. The appreciation of a close link
between treatment and thromboembolic complications has been
difficult for  the underlying increased tendency to thrombosis of
cancer per se and required careful epidemiological evaluation (13-
15). The main mechanisms of thrombogenesis associated with
chemotherapeutic agents are: 1) The release of procoagulants
and cytokines from tumor cells damaged by the cell-targeted
treatment; 2) A toxic effect directed towards vascular endotheli-
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Effect of CMF-chemotherapy on blood
coagulation in patients with breast cancer
C
BACKGROUND: Influences of CMF (cyclophosphamide, methotrexate, 5-fluorouracil)
chemotherapy on blood coagulation were investigated in 30 patients receiving adjuvant
chemotherapy and in 30 patients receiving chemotherapy for metastatic breast cancer. 
METHODS: In plasma samples of 60 patients (median age 49.5), we evaluated the fol-
lowing parameters: 1) Markers of in vivo clotting activation thrombin-antithrombin
complex ( ELISA) and D-dimer (ELISA), 2) Natural anticoagulants (protein C [PC] and
antithrombin III [AT III] by chromogenic methods). The coagulation studies were per-
formed at the beginning and at the end of the first cycle of CMF protocol.
RESULTS: Before CMF therapy, significant difference was observed between patients
with early stage and patients with metastatic breast cancer in the PC (p<0.01), AT III
(p<0.01) and TAT (p<0.01) levels. After CMF therapy, patients with stage II (adjuvant)
disease manifested a significant decrease in the level of PC and AT III activity (p<0.01)
and an increase in TAT level (p<0.01). In patients with disseminated breast cancer
CMF therapy provoked an increased level of TAT and D-dimer with a decreased activi-
ty of protein C and antithrombin III. There was significant difference in value of TAT, D-
dimer, protein C and antithrombin III between the patients with adjuvant and metastat-
ic breast cancer patients after CMF chemotherapy.
CONCLUSION: Our results suggest that the application of cytotoxic therapy provokes
hypercoagulable condition in breast cancer patients. This effect should be considered
when chemotherapy is employed in advanced cancer patients at high risk for throm-
bosis, or in patients with other risk factors.
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61um; 3) the fall of naturally occurring anticoagulants (protein C,
protein S, antithrombin III) (13,16-20).
This study evaluated alterations of coagulative parameters :1)
Markers of in vivo clotting activation (thrombin-antithrombin com-
plex [TAT] and D-dimer), 2.  Natural anticoagulants (protein C
[PC] and antithrombin III [AT III]) following CMF chemotherapy in
patients with breast cancer. Topics of this study were: 1)
Detection of laboratory markers of activation of coagulation dur-
ing CMF chemotherapy; 2) Changes in the plasma level of natur-
al coagulation inhibitors- protein C and antithrombin III; 3)
Differences in plasma level of TAT, D-dimer, PC and AT III
between patients with localized and patients with disseminated
breast cancer during CMF chemotherapy.
PATIENTS AND METHODS
Our research considered 60 patients with malignant breast
tumors, diagnosed and treated at the Institute of Oncology in
Sremska Kamenica from January 1997 to the end of 2000. All the
patients received CMF chemotherapy: a) 30 of them were treated
in adjuvant setting, b) the other  30 were treated for metastatic
breast carcinoma.
At the Institute of Oncology in Sremska Kamenica the following
cytostatic CMF scheme was applied: cyclophosphamide 300
mg/m2 days 1-5, methotrexate 20 mg/m2 days 1, 3 and 5, 5-flu-
orouracil 500 mg/m2 days 2 and 4. Chemotherapy was repeated
in every 28 days. 
Criteria for inclusion of patients in our studies were: radical mas-
tectomy, which was done in 40 patients (66.7%), segmental
resection in 20 patients (33.3%) and axillary dissection in all
patients. Histological diagnosis of breast cancer was confirmed:
ductal carcinoma in 44 patients (73.3%), lobular carcinoma in 7
(11.7%) and mixed (ductal and lobular) in 9 patients (15%). For
the diagnosis of metastatic disease the following examinations
were done: routine laboratory tests, chest X ray, ultrasonography
of abdomen, bone scan, also computed tomography of the chest
and abdomen, magnetic resonance of CNS and, if necessary,
magnetic resonance of bones. Histological verification of the out-
spread of disease was established by cytological examination of
pleural puncture, liver and bone biopsy. The stage of disease was
established according to the criteria of UICC and EORTC from
1997. Of 60 examined patients, 30 were in stage II (adjuvant) and
30 with metastatic disease. Patients’ median age was 49.5
(range, 30-71 years); of 60 patients 32 (53.3%) and 28 (46.7%)
were in pre-and postmenopausal status, respectively. 
The median age of the patients with stage II (adjuvant) breast can-
cer was 48 years (range, 35-71 years), and of patients with stage
IV it was 52 years (range, 30-65 years). Patients who previously
received adjuvant chemotherapy were not treated with radiation or
hormonal therapy. Twelve of 30 patients with metastatic breast
cancer  received hormonal therapy (Tamoxifen) but radiation was
applied in all patients (Table 1). Patients started with CMF treat-
ment at least 28 days after the end of previous therapy. 
No patients presented clinically evident signs of thromboembolic
disease, disseminated intravascular coagulation (DIC), and hem-
orrhage syndrome, and they were not treated with anticoagulant
therapy. 
The following parameters were studied:
1. Markers of in vivo clotting activation thrombin-antithrombin
complex and D-dimer, 
2. Natural anticoagulants (protein C and antithrombin III).
All tests were performed before CMF chemotherapy and immedi-
ately after the first cycle. 
Laboratory tests
To avoid diurnal variation, blood was always collected in the
morning (between 7 a.m. and 9 a.m.). Blood samples obtained by
untraumatic venepuncture were put into plastic tubes containing
one-ninth volume of balanced citrate. Hematological parameters
were measured in citrated plasma after centrifugation of 3,000 g
at 40¡C for 20 min. The obtained plasma was immediately frozen
and stored at -70¡C. 
Thrombin-antithrombin complex was measured by enzyme-linked
immunoadsorbent assay (ELISA; Enzygnost TAT [Behring]).
Normal range: 2-4 ￿g/L.
D-dimer was measured by the latex agglutination assay for the
semi-quantitative determination of fibrin D-dimer in human plas-
ma or serum (ACCUCLOT TM D-dimer  SIGMA). Normal range: <
250 ng/ml.
Antithrombin III was measured by the chromogenic substrate
Berichrom-Antithrombin III (Behring) for Chromotimer (Behring).
Normal range: 80-120%. Protein C was measured by the chro-
mogenic substrate Berichrom-Protein C (Behring) for
Chromotimer (Behring). Normal range: 70-140%.
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Table 1. Characteristics of patients groupsStatistical analysis
All statistical analyses were performed using the BMDP software
1990 Revision package. Results are expressed as the mean –
SD and median. Comparisons of means between paired data
were performed using the matched paired t test. Comparisons
between groups of quantitative data were performed using the
Mann-Whitney rank sum U test (two groups of non-paired data).
Chi-squared and Wilcoxon matched pairs tests were used.
RESULTS 
Sixty women with breast cancer were treated with CMF
chemotherapy, and were considered eligible.
The pretreatment level of TAT was in normal range in 90%
(27/30) of patients treated with adjuvant chemotherapy and it was
increased in 56.7% (17/30) of patients treated for metastatic dis-
ease.
D-dimer was noted in 50% (15/30) of patients receiving adjuvant
chemotherapy and in 56.7% (17/30) of patients with disseminat-
ed breast carcinoma. 
The pretreatment plasma level of natural coagulation inhibitors PC
and AT III were in normal range with almost all patients.
The median pretreatment value of TAT in patients receiving adju-
vant chemotherapy was 2.82 ￿g/L, whilst in patients with stage
IV it was 4.45 ￿g/L. There was significant difference in pretreat-
ment values of TAT between patients on adjuvant setting and
patients with stage IV breast carcinoma (Table 2).
The median pretreatment value for protein C was 121.93% in
patients with stage II (adjuvant), whilst in patients with stage IV it
was 99.52%. Comparisons revealed that the pretreatment value
of protein C was statistically significantly higher in patients with
stage II (adjuvant) than in patients with stage IV breast carcinoma
(Table 2).
There was significant difference in pretreatment value of AT III
between patients with stage II (adjuvant) and stage IV breast can-
cer. The patients with localized breast carcinoma showed signifi-
cant elevations of AT III when compared with patients with dis-
seminated breast carcinoma (Table 2).
There was no statistically significant difference in pretreatment
value of D-dimer between patients with stage II (adjuvant) and
patients with stage IV breast carcinoma (Chi-square test;
p=0.60).
The pretreatment levels of TAT were within normal range (2.16-
8.55 ￿g/L) in all patients who received adjuvant therapy for breast
carcinoma and increased in 33% of patients (2.32-7.68 ￿g/L)
after the first cycle of chemotherapy. There was significant differ-
ence in TAT value between pre- and post-treatment value (Table
3). The average difference between the pre- and post-treatment
value was 0.616–0.98 ￿g/L.
At the beginning of the first cycle of CMF therapy, protein C lev-
els were in normal range in most patients treated with adjuvant
chemotherapy for breast carcinoma and it remained in normal
range after the termination of chemotherapy. Protein C level
decreased in almost all patients during CMF therapy. There was
significant difference in Protein C activity between pre- and post-
treatment value (Table 3). The average difference between the
pre- and post-treatment value was 21.08–13.50%.
At the beginning of therapy antithrombin III was increased in 33%
(10/30) of patients who received adjuvant CMF therapy but it was
decreased in 20% (6/30) of patients after the termination of
chemotherapy. Before and after chemotherapy, statistically rele-
vant difference existed for mean level of antithrombin III (Table 3).
The average difference between the pre- and post-treatment value
was 17.11–13.30% (Table 4).
Cross-linked fibrin derivatives (D-dimer) were noted before
chemotherapy in 15 of 30 patients who received adjuvant thera-
py for breast carcinoma, and in 19 of 30 patients after chemother-
apy. There was no significant difference in D-dimer between pre-
and post-treatment value.
Before chemotherapy an increase of TAT was noted in 17 of 30
patients with disseminated breast carcinoma, and it was
increased in 27 of 30 patients after the first cycle of CMF
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Table 2. The pre-treatment values of hemostatic parameters quantified in patients
with stage II (adjuvant) (N=30) and in the patients with stage IV (N=30) breast
carcinoma
Table 3. Results of coagulation tests in 30 patients with stage II (adjuvant) breast
carcinoma before and after CMF chemotherapy (mean – SD)
Table 4. Results of coagulation tests in 30 patients with stage IV breast carcino-
ma before and after CMF chemotherapy(mean – SD)chemotherapy. When the value of TAT after treatment was com-
pared with the pretreatment value, a significant difference was
observed (Table 4). The average difference between pre- and
post-treatment value was 2.53–1.36 ￿g/L.
The pretreatment level of natural coagulation inhibitor protein C
was within normal range with almost all patients and it remained
in normal range after the first chemotherapy cycle finished.
Protein C activity was significantly reduced after the termination
of chemotherapy when compared to pretreatment activity (Table
4). The average difference between the pre- and post-treatment
value was 19.38–10.26%.
Before and after CMF chemotherapy, antithrombin III level was in
normal range within all patients with stage IV breast carcinoma.
There was significant difference in antithrombin III value between
pre- and post-treatment value (Table 4). The average difference
between the pre- and post-treatment value was 7.25–4.64%.
D-dimer was observed before chemotherapy in 17 of 30 patients
with disseminated breast carcinoma, and in 24 of 30 patients
after the termination of chemotherapy. There was significant dif-
ference between pre- and post-treatment D-dimer value
(Wilcoxon matched pairs test: p< 0.01).
The median values, ranges of the parameters studied in patients
with stage II (adjuvant) and patients with stage IV after CMF
chemotherapy are presented in Table 5. There was significant dif-
ference in TAT post-treatment value between patients with stage
II (adjuvant) and those with stage IV breast carcinoma (Table 5).
TAT value was increased in patients with metastatic breast carci-
noma. Protein C activity was significantly decreased in patients
with disseminated breast carcinoma (Table 5). Antithrombin III
was significantly decreased in patients with stage IV breast carci-
noma (Table 5). There was no significant difference in D-dimer
value after chemotherapy between patients with stage II (adju-
vant) and patients with stage IV breast carcinoma.
DISCUSSION
Malignancy is known to be associated with an increased inci-
dence of thromboembolic disease. It has been shown that iatro-
genic influences, such as surgery (21), radiotherapy (9)  and
chemotherapy  (17-20,22) potentially increase the risk for throm-
bosis in cancer. Previous reports have implicated an association
of chemotherapy and increased incidence of thrombosis in
women with breast cancer (17-19). Patients with breast cancer
are found to develop thrombosis in 2.2% to 17.6% of cases when
treated with CMF chemotherapy, and the risk is highest in patients
treated for metastatic disease (12,23). These observed inci-
dences were far greater than the average incidences in similar
cancer patients not receiving chemotherapy. The etiology of the
increased incidence of thromboembolic events in breast cancer
patients receiving chemotherapy is not known. The potential risk
of chemotherapeutic agents for increasing  tendency to develop
thrombosis is difficult to evaluate as other risk factors often pre-
dispose cancer patients to thromboembolic complications.
In our study observed the changes of markers of clotting activa-
tion-TAT and D-dimer, and natural clotting inhibitors protein C and
antithrombin III during CMF chemotherapy in breast cancer
patients. At the beginning of CMF chemotherapy, marker of acti-
vation of clotting-TAT was significantly increased while there was
no difference in D-dimer levels in patients with disseminated
breast cancer in comparison with patients with localized disease.
The higher levels of natural clotting inhibitors (PC and AT III) were
noted in patients who received adjuvant therapy for breast carci-
noma when compared with the values of patients with metastatic
disease. As we know, in advanced breast cancer disease there is
a natural tendency towards thrombosis. In most of the patients
with metastatic cancer subclinical activation of blood coagulation
is evident (3,6,24). This was a background for the consideration
of our results.
After CMF chemotherapy, in majority of patients on adjuvant set-
ting significant increases in TAT levels were noted, followed by
significant decreases in PC and AT III levels. The value of natural
inhibitor of coagulation was within normal range. The increase
TAT level indicated activation of blood coagulation during CMF
chemotherapy. Our results were similar with the results of other
studies (7,9,16-20,22).
The mechanisms for depression of natural inhibitors of coagula-
tion noted in our patients are unclear. The first possible mecha-
nism could involve the known inhibition of DNA and RNA synthe-
sis by CMF chemotherapy leading to decrease in protein synthe-
sis in the liver, and lowering of plasma levels of protein C and
antithrombin III (25). In addition, we cannot exclude the possibil-
ity of functional disorder of natural inhibitor of blood coagulation.
Also, we cannot exclude the possibility of functional disorder of
protein C as a resistance to activated protein C or a disorder in
carboxylation of PC in liver under the influence of 5-FU (26). The
other possible mechanism could be the initiation of intravascular
coagulation by cytostatics. In malignant diseases the incidence of
disseminated intravascular coagulation (DIC) is increased (3-5,
8). Decrease of plasma levels of PC and AT III (27) is evident at
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Table 5. Results of coagulation tests in 30 patients with stage II (adjuvant) and
stage IV of breast carcinoma after CMF chemotherapyDIC. In our study, however, we did not measure the antigenic level
of protein C and antithrombin III, so we were able to evaluate their
activity alone, which was declined after chemotherapy. Enhanced
values of TAT are also observed at intravascular coagulation (27).
The increase of TAT values, noticed in our study, could suggest
the activation of coagulation. As a result of initiation of coagula-
tion the thrombin is produced and neutralized by antithrombin III,
linking to it and forming TAT. During this process antithrombin III
is consumed, declining its level in plasma. This could be the
acceptable explanation of the results in our study. The third mech-
anism could be a disorder in absorption and metabolism of vita-
min K caused by cytostatics, which could explain decrease of
protein C noticed in our study (28). In any case, reduction of
activity of the two inhibitors suggests the presence of throm-
bophilic state. 
In more than half of patients with metastatic breast cancer
pretherapeutic values of TAT are elevated, and implicate the
raised production of thrombin.  Our results are similar to results
of other authors (8,23,27,28). After the therapy, in higher per-
centage of patients TAT level is elevated. The cause of these
processes might be either  the coagulation  activation or declined
antithrombin activity, or both of them. In our work, we found that
in this group of patients the activity of AT III and PC, powerful
inhibitors of coagulation, was significantly lowered after CMF
therapy (12,29-31). These changes move the equilibrium of
coagulation mechanism towards prethrombotic state.
D-dimer is detected in 60% of patients before the therapy, and
after the therapy in 80% of patients. The study of Falanga et al.,
reporting similar data about increased values of D-dimer before
therapy that remain on high level after therapy, confirms our
results (28). The presence of D-dimer proves that proteolytic
digestion of fibrin under the influence of plasmin is performed in
vivo and fibrinolytic system is activated (32). In the meantime, D-
dimer indirectly shows presence of thrombin and activation of
coagulation process. In our study, increased thrombin activity in
patients with stage IV of breast cancer was registered, and this
could explain the higher level of D-dimer.
The alterations in coagulation parameters due to chemotherapy
were similar between patients with metastatic and localized dis-
ease. The coagulation studies in these patients showed low-grade
intravascular clotting activation and a reduction of antithrombin III
and protein C. The increase of TAT levels following CMF
chemotherapy was noted in majority of patients with breast can-
cer. The decrease in plasma protein C and antithrombin III levels
as a result of chemotherapy was observed in almost all of our
patients. None of our patients developed clinically apparent
thrombotic event.
CONCLUSION
This study provides suggestive evidence of an effect of
chemotherapy towards hypercoagulability. The results of this
study indicate that before therapy,  hypercoagulable state is pre-
sent in stage IV of breast cancer. After chemotherapy, abnormal-
ities of hypercoagulation markers persist which was not indicat-
ed in stage II. This observation suggests for caution when using
anticancer drugs in some patients. In advanced breast cancer
patients, where an increased incidence of thrombosis occurs nat-
urally, the combination of chemotherapy with other drugs that are
reported to induce hypercoagulability, especially in patients with
other additional risk factors, should be carefully evaluated.
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